

Contents

1

Introduction

- 1.1 Deal-making in the pharmaceutical industry
- 1.2 Understanding value creation
- 1.3 Purpose

2

Valuation methods

- 2.1 Integrated methodologies
- 2.2 Why use eNPV and Benchmarking?
- 2.3 Other methods
 - 2.3.1 Internal Rate of Return (IRR)
 - 2.3.2 Payback
 - 2.3.3 Real Options

3

Benchmarking

- 3.1 Introduction to benchmarking
- 3.2 Feasibility
- 3.3 Data gathering
- 3.4 Approximate valuation
- 3.5 Refinement of the valuation
- 3.6 Example: Cancer
 - 3.6.1 Phase I benchmarking example
 - 3.6.2 Phase II benchmarking example
 - 3.6.3 Phase III benchmarking example
 - 3.6.4 Summary

4

Expected Net Present Value (eNPV)

- 4.1 Basics
- 4.2 Opportunity cost / time value
 - 4.2.1 Example NPV calculation
- 4.3 Risk of R&D failure
- 4.4 Decision Tree Analysis
 - 4.4.1 Example eNPV calculation
- 4.5 eNPV Summary
- 4.6 Example: Valuation of PRI-123
 - 4.6.1 Input data and assumptions
 - 4.6.2 The spreadsheet model
 - 4.6.3 More complex models
 - 4.6.4 Binomial model for PRI-123

4.7 Further refinement of the eNPV model

- 4.7.1 Sensitivity analysis
- 4.7.2 Monte-Carlo Simulation

4.8 Options contracts - which method to use?

5

Agreement Structure

- 5.1 Value split
- 5.2 Risk sharing
- 5.3 Deal components
 - 5.3.1 Upfront payments
 - 5.3.2 R&D funding
 - 5.3.3 License fees
 - 5.3.4 Milestones
 - 5.3.5 Royalties
 - 5.3.6 Shared costs or benefits
 - 5.3.7 Equity
- 5.4 Preferences (utility)
- 5.5 Example: Deal Structure for PRI-123

6

Valuation of Technologies

- 6.1 Drug delivery technology
 - 6.1.1 Enabling technology
 - 6.1.2 Enhancing technology
 - 6.1.3 Extension of patent life
- 6.2 Drug discovery technology
- 6.3 Example: Valuation of drug delivery enhancement of PRI-123

7

Conclusion

Appendix

Cancer deals

Figures

- 1 Total licensing activity in the pharmaceutical industry
- 2 Average upfront and headline value by year and phase
- 3 Integrated valuation methods
- 4 Binomial lattice modelling of Brownian movement in value
- 5 eNPV decision-tree model with scenario analysis for commercial risk
- 6 Ideal benchmarking deal cluster
- 7 Non-ideal benchmarking cluster
- 8 PharmaDeals® Agreements database search engine
- 9 Example pharmaceutical deal valuation force field
- 10 Attrition by phase and therapeutic area
- 11 Example decision tree
- 12 Pharmaceutical product decision tree
- 13 Example decision tree
- 14 Monte-Carlo simulation for PRI-123
- 15 The effect of time and risk on the value of deal components
- 16 A rough guide to NPV split ratios
- 17 Frequency of equity investment as financial component
- 18 Enhanced revenues due to delivery technology
- 19 Enhancement of patent life
- 20 Drug discovery decision tree model
- 21 Extended drug discovery decision tree model
- 22 Drug discovery eNPV model
- 23 Value of the PRI-123 delivery technology

Tables

- 1 Pros and cons of benchmarking and DCF-based methods
- 2 Benchmarking methodology overview
- 3 Sources of benchmarking information
- 4 Useful websites
- 5 Approximate benchmark valuation
- 6 Refined benchmark valuation
- 7 Phase I small molecule anti-cancer deals
- 8 Phase II small molecule anti-cancer deals
- 9 Phase III small molecule anti-cancer deals
- 10 Cost of capital (COC) for pharmaceutical firms
- 11 Example NPV calculation – part 1: Contribution
- 12 Example NPV calculation – part 2: NPV
- 13 Selected examples of data sources providing estimates for success and attrition in drug development
- 14 Example eNPV calculation
- 15 Cumulative probabilities
- 16 Example valuation - summary
- 17 eNPV spreadsheet valuation of PRI-123
- 18 Quarterly eNPV spreadsheet for PRI-123
- 19 Valuation of PRI-123 using the binomial method
- 20 Sensitivity analysis of the PRI-123 model
- 21 PRI-123 deal structure and eNPV share
- 22 PRI-123 eNPV valuation and deal structure spreadsheet model
- 23 eNPV model for enhanced PRI-123 formulation